Valeant's ($VRX) next pickup could come from the Middle East, where it's reportedly in deal talks with one of Egypt's largest drugmakers, Amoun. That company could fetch between $700 million and $800 million, Bloomberg's sources say, though the talks are still in the early stages. Amoun would be Valeant's third conquest since losing out on longtime target Allergan, following acquisitions of Salix and the assets of bankrupt biotech Dendreon. If a transaction between the pair doesn't go through, though, Amoun could go the IPO route, Bloomberg reports. More